U.S. Markets open in 4 hrs 46 mins

AXIM Biotechnologies, Inc. (AXIM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4300+0.0100 (+2.38%)
At close: 3:47PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4200
Open0.4200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4050 - 0.4549
52 Week Range0.1000 - 1.4400
Volume243,941
Avg. Volume140,958
Market Cap53.835M
Beta (5Y Monthly)-0.26
PE Ratio (TTM)N/A
EPS (TTM)-0.0570
Earnings DateMay 01, 2018 - May 07, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
    GlobeNewswire

    AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity

    SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, applauds the recent announcement from a major vaccine producer that it has achieved 90 percent efficacy in its COVID-19 vaccine trial. With this news, the Company highlights that its rapid diagnostic test will be vital in analyzing vaccine recipients’ immunity to COVID-19 post-vaccination. As a solution, AXIM has developed one of the only point-of-care rapid diagnostic tests for measuring COVID-19 neutralizing antibodies in plasma or serum after vaccination.The goal of all COVID-19 vaccines undergoing clinical trials is to elicit neutralizing antibodies that block the virus from infecting an individual. After vaccination, the only way for manufacturers to measure vaccine efficacy is to measure their levels of neutralizing antibodies. If their neutralizing antibody levels are low, the vaccine was not effective for that person (i.e. he/she can still become infected and spread the virus despite being vaccinated). If neutralizing antibody levels are high, they are be protected from disease. Additionally, no one knows how long the antibodies from vaccines will last and whether a booster shot might be necessary.Since we know the COVID-19 vaccine will not elicit protective immunity in every individual and variable immunity in others, the challenge is to measure levels of protective immunity in vaccine recipients. This is a tall order. It is not logistically possible to take a tube of blood from even a small portion of the vaccinated population and send to clinical laboratories for testing. AXIM’s point-of-care rapid diagnostic test solves these challenges because it takes only 10 minutes to measure neutralizing antibody levels. AXIM’s test is portable, cost-effective and provides users with information about their level of protective immunity.“As news broke this week about successful vaccine trial data for COVID-19, the world will soon be looking for a faster, more affordable way to ensure that those who receive the vaccine are indeed protected,” said AXIM® Biotech CEO John W. Huemoeller II. “While there are other neutralizing antibody tests available, ours, unlike others, will be the only option available in a point of care setting and it will provide the most rapid results on the market. No vaccine can be 100 percent effective but we want to be at the forefront of helping to guarantee that those who receive a COVID-19 vaccine know if they are immune or need to seek alternative measures to achieve immunity. This could greatly reduce the spread of the virus.”About AXIM® BiotechnologiesFounded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.Public Relations Contact: Kathryn Reinhardt Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comCorporate Contact Info: North American Address: 45 Rockefeller Plaza, 20th Fl. New York, NY 10111, USA P. 844 294 6246FORWARD-LOOKING DISCLAIMERThe statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive  clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.LEGAL DISCLOSUREAXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

  • AXIM® Biotechnologies Issues Update Letter to Shareholders
    GlobeNewswire

    AXIM® Biotechnologies Issues Update Letter to Shareholders

    SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans. Highlights of the letter include:1) The Company’s rapid pivot and response to COVID-19, including:      • Developing World’s First Rapid Diagnostic Test for Detecting Neutralizing Antibodies   -Status: Emergency Use Authorization (EUA) filed with the FDA   -Signed distribution and manufacturing agreement   -Will be conducting a live virus comparison study on 30 plasma samples at a Biosafety Level 3 (BSL3) laboratory   -Received Institutional Review Board approval to begin a clinical study at Arizona State University with the Company’s point-of-care whole blood test   -Expect to see significant revenue in the coming months       • NeuCovix-HT™: A high throughput, patent-pending diagnostic test that measures levels of functional antibodies in plasma or serum that neutralize the SARS-CoV-2 (COVID-19) virus   -Status: EUA filed with the FDA       • World’s First Face Mask Designed to Capture COVID-19 Virus   -Additional testing is ongoing       • Virus Binding Protein (VBP)   -Filed a provisional patent application on September 22, 2020, relating to the invention of a VBP that is more potent, has a longer shelf life and is more stable than wild type ACE2   -In addition to current use in AXIM’s neutralizing antibody tests and face mask, the invention relates to the use of the VBP for the treatment and diagnosis of various disorders.   -This now in-house development of the core ingredients needed to manufacture strips and masks could potentially lead to additional revenue and allows AXIM to control its supply chain.       2)The Company’s recent oncology-focused research updates, including:          •New Patent re: SBI-183   -This new patent validates the novelty of SBI-183 as an inhibitor of tumor growth, invasion and suppression of metastasis, which is the parent compound for the Company’s work with SBI-183 analogs with the end goal of identifying the most potent QSOX1 inhibitors. Claims relate to the treatment of neoplastic cells in a variety of cancers, including myeloma, breast, kidney, and pancreas.        •Conversion of Provisionals re: SBI-183 Analogs   -One or more of these analogs have been shown in animal studies to be up to 10 times more potent than the parent compound, SBI-183.       •A recently awarded $395,880 phase I Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to continue research and development of novel small molecules that inhibit the enzymatic activity of QSOX1 based on SBI-183. This success has allowed AXIM to bring on additional staff that are dedicated to the research and development of these analogs.     3) The Shareholder Letter details some of the Company’s anticipated key milestone achievements for the end of 2020 and beginning of 2021. The Company’s Chief Executive Officer John W. Huemoeller II commented: “2020 has been an unexpected and unprecedented year for every industry. I am so proud and humbled by the ability of AXIM’s scientists to swiftly adapt their skills into COVID-19 research and development at the onset of the pandemic. Together, we have brought several much-needed, first-of-its-kind rapid tests to fruition and have done so in a fiscally responsible way that maximizes our budget. In 2021, we look forward to further partnerships and developments as we work to bring our COVID-19 projects to market and continue our oncology-focused research.” To read the Letter to Shareholders in full, please visit: https://aximbiotech.com/investors/.About AXIM® BiotechnologiesFounded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. The Company has also begun development of the first-ever face masks that capture and deactivate SARS-CoV-2, enhancing protection of both the user and those surrounding the user. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.Public Relations Contact: Kathryn Reinhardt Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comCorporate Contact Info: North American Address: 45 Rockefeller Plaza, 20th Fl. New York, NY 10111, USA P. 844 294 6246FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.LEGAL DISCLOSUREAXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

  • GlobeNewswire

    Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)

    SAN DIEGO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has filed a provisional patent for the first-ever face mask that captures and deactivates SARS-CoV-2, the coronavirus responsible for the ongoing COVID-19 pandemic. “Due to the COVID-19 pandemic, the demand for face masks has grown exponentially and is expected to reach $21.2 billion by 2026 as the scientific data continues to support their ability to lessen risk of infection. AXIM’s face mask has a place in almost every setting and could be revolutionary in helping the world achieve its goal of slowing the spread of COVID-19 both in healthcare and everyday circumstances,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are proud to support an investment company innovating such creative and necessary solutions as we all fight this pandemic together.”Most commercially available masks are unable to efficiently filter the tiny aerosols that contain the virus. Viruses that are attached to the filtering materials can penetrate through a moist mask and, thus, increase the risk of infection. Noting this major issue, AXIM designed its novel face mask to provide enhanced protection from infection by capturing viruses in the face mask filter layer before they reach or after they exit the user's respiratory system.To accomplish the goal of capturing SARS-CoV-2 on the face mask, AXIM utilizes a proprietary set of reagents that are permanently embedded into the mask filter and capture the virus instantaneously on contact. AXIM’s initial laboratory testing has demonstrated that the SARS-CoV-2 spike protein tightly binds to the capture reagents finely interspersed throughout its face mask fibers, therefore significantly increasing the mask’s ability to effectively capture the virus when compared to commercially available masks.“SARS-CoV-2 viruses are significantly smaller than the fibers within commercially available masks and so, inevitably, at least some end up passing through the mask. By coating the filtration layers of our face masks with our proprietary reagents, which SARS-CoV-2 binds to, we can ‘capture’ the virus in the masks to provide enhanced protection and lower the rate of COVID-19 infection,” said AXIM® Biotech CEO John W. Huemoeller II.Currently, AXIM is examining the regulatory pathways necessary to obtain approval to distribute the face mask in the U.S., either through the Food and Drug Administration (FDA) or the Environmental Protection Agency (EPA), and in the European Union. AXIM plans to license face mask manufacturers to handle large-scale production and distribution of the face mask while manufacturing the preparatory reagent ingredients in its own laboratory. To learn more about AXIM’s COVID-19-related research, please visit https://aximbiotech.com/.About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT: Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 858-264-6600 andrew.hard@cmwmedia.com www.cmwmedia.comInvestor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com